Simplify Propel Opportunities ETF Rating $16.26 +0.33 (+2.07%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Simplify Propel Opportunities ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.SURI Aggregate RatingModerate Buy 2.58Holdings in SURI have an aggregate rating of Moderate Buy based on 138 analyst ratings issued in the past year covering 18 companies (93.1% of the portfolio).SURI Aggregate Price Target$16.26High Prediction$16.26Average Prediction$16.26Low Prediction$16.26Holdings in SURI have an aggregate price target of $16.26 and a range of $16.26 to $16.26 covering 18 companies (93.1% of the portfolio).SURI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy9 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Simplify Propel Opportunities ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 18 SURI Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings35.67%PAGPPlains GP$21.95+2.4%2.584 of 5 stars2.22$20.22 -7.9%911.06%MDGLMadrigal Pharmaceuticals$307.08+4.6%4.5653 of 5 stars2.69$351.67 14.5%137.95%AKROAkero Therapeutics$25.60+1.8%3.9442 of 5 stars2.88$46.83 82.9%85.66%PHATPhathom Pharmaceuticals$6.79-2.4%2.4579 of 5 stars2.75$23.00 238.7%4High Trading Volume5.16%RNAAvidity Biosciences$30.84+6.6%1.1042 of 5 stars3.00$65.80 113.4%10Analyst Forecast4.90%ARDXArdelyx$4.91-2.0%3.675 of 5 stars2.75$9.25 88.4%84.06%TCRXTScan Therapeutics$2.37-1.3%2.4394 of 5 stars3.00$11.25 374.7%43.80%CASHPathward Financial$78.43+0.9%3.4257 of 5 stars2.50$92.00 17.3%2Earnings Report3.18%ABEOAbeona Therapeutics$5.19-0.6%3.3179 of 5 stars3.00$18.00 246.8%32.68%APLTApplied Therapeutics$0.66+0.3%4.4393 of 5 stars2.57$6.10 831.0%7Short Interest ↑Gap Down2.20%SNDXSyndax Pharmaceuticals$13.67+4.5%3.7635 of 5 stars2.90$36.20 164.8%101.63%KYMRKymera Therapeutics$43.70+7.6%2.7733 of 5 stars2.88$55.06 26.0%17Analyst ForecastGap Up1.36%ZVRAZevra Therapeutics$8.15+1.2%2.0653 of 5 stars3.13$21.57 164.7%81.18%ATHAAthira Pharma$0.54+1.7%3.609 of 5 stars2.00$13.83 2,465.1%4Gap Up1.03%ACHVAchieve Life Sciences$2.85-7.8%2.0233 of 5 stars3.33$14.80 419.3%6News Coverage0.82%KURAKura Oncology$7.39+1.8%4.482 of 5 stars2.91$27.38 270.4%110.60%DCTHDelcath Systems$14.98+4.7%3.6155 of 5 stars3.00$22.25 48.5%40.20%JSPRJasper Therapeutics$5.70+3.4%2.7746 of 5 stars3.00$67.75 1,088.6%10Short Interest ↑ This page (NYSEARCA:SURI) was last updated on 1/21/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Simplify Propel Opportunities ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Simplify Propel Opportunities ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
